Koers Evogene Ltd. TEL AVIV STOCK EXCHANGE
Aandelen
EVGN
IL0011050551
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 17 mln. 64,69 mln. 15,89 mln. | Omzet 2025 * | 31,5 mln. 120 mln. 29,44 mln. | Marktkapitalisatie | 33,94 mln. 129 mln. 31,72 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -20 mln. -76,11 mln. -18,69 mln. | Nettowinst (verlies) 2025 * | -17 mln. -64,69 mln. -15,89 mln. | EV/omzet 2024 * | 2 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 1,08 x |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,34% |
Recentste transcriptie over Evogene Ltd.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 01-01-02 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 01-04-22 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 01-01-05 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 17-11-21 |
Sarit Firon
CHM | Chairman | 58 | 11-08-16 |
Leon Recanati
BRD | Director/Board Member | 76 | 01-05-05 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,89% | 42,59 mld. | |
+8,49% | 40,65 mld. | |
+49,22% | 40,57 mld. | |
-12,36% | 26,77 mld. | |
+8,54% | 24,81 mld. | |
-24,26% | 18,17 mld. | |
+28,75% | 12,05 mld. | |
-2,88% | 11,7 mld. | |
+6,83% | 11,1 mld. |